155.25USD+0.23%Mkt Cap: —P/E: 211.951d ago
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products i…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value15.78B $
Revenue (TTM)3.37B $
Gross Profit2.18B $
Net Income (TTM)705.50M $
Revenue/Share33.66 USD
Last Price155.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS64125C1099
Valuation
P/E (Trailing)211.95
P/E (Forward)—
PEG—
EV/EBITDA17.27
EV/Revenue4.68
P/S—
P/B4.24
EPS (TTM)0.73
EPS (Forward)—
52W Range
153.3726% of range160.66
52W High160.66 USD
52W Low153.37 USD
Profitability
Gross Margin64.48%
Oper. Margin22.19%
EBITDA Margin27.07%
Profit Margin20.91%
ROE22.09%
ROA11.70%
Growth
Revenue Growth39.50%
Earnings Growth31.10%
Cash Flow & Leverage
Operating CF898.10M $
CapEx (TTM)—
FCF Margin18.92%
FCF Yield—
Net Debt71.80M $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity12.50
Current Ratio1.87
Quick Ratio1.46
Book Value/Sh36.35 USD
Cash/Share3.835 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.90.68M
Float100.39M
Insiders1.06%
Institutions102.80%
Technical
SMA 50135.58 (+14.5%)
SMA 200114.15 (+36.0%)
Beta0.39
S&P 52W Chg20.80%
Avg Vol (30d)151
Avg Vol (10d)390
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—